Analysis of phosphoinositide variants in ovarian and endometrial cancers

Not Applicable

Recruiting

• Conditions: ovarian cancer, endometrial cancer; D010051, D016889

• Registration Number: JPRN-jRCT1030220526
• Lead Sponsor: Satoh Toyomi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-12-23
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 200

Inclusion Criteria

Patients who received surgeries for ovarian cancer or endometrial cancer at our hospital between the date of approval by the review board and September 30, 2027, and whose tumor tissue, ascites, or blood samples are stored at the Tsukuba Human Tissue Biobank Center.

Exclusion Criteria

none

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evels of phosphoinositide variants in tumor tissue, ascites, or blood samples, results of PIK3CA and PTEN gene sequencing, age, histopathological diagnosis, stage, overall survival, cancer-specific survival, progression-free survival, recurrence-free survival, treatment-free interval, and therapeutic efficacy, etc.